Cantor Fitzgerald Reiterates Pacific Biosciences of California (PACB) at Overweight, $23 PT, Corteva Collaboration Further Demonstrates Power of PACB's Hifi Technology
Tweet Send to a Friend
Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $23.00 price target on Pacific Biosciences of California (NASDAQ: PACB) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
